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Abstract
After the cDNA of human macrophage migration inhibitory factor (MIF) was cloned in 1989, this protein has been re-
evaluated as a pro-inflammatory cytokine, pituitary hormone and glucocorticoid-induced immunoregulatory protein. We
previously reported the expression of MIF in the basal cell layers of the epidermis, but its pathophysiological function in the
skin has not been well understood. In this study, we examined the expression of MIF during the wound healing of rat skin
injured by excision. Reverse transcription-polymerase chain reaction in combination with Southern blot analysis revealed
that the increase of MIF mRNA expression was biphasic. The maximum peaks were observed at 3 and 24 h after the injury.
Similarly, maximal increases of the serum MIF level were observed at 3 and 24 h after the injury. Immunohistochemical
analysis at 12 h after injury demonstrated enhanced expression of MIF protein in the whole epidermal lesion of the wound
tissue. By the Boyden chamber assay, we demonstrated that MIF had a chemotactic effect on freshly prepared keratinocytes
from rat skin. Additionally, cultured fibroblasts from the skin wound lesion secreted a higher amount of MIF in response to
lipopolysaccharide compared to those of the normal skin. Furthermore, administration of anti-MIF antibodies induced a
delay of wound healing in vivo. Taken together, these results suggest that MIF contributes to the wound healing process of
skin tissue. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Evidence is emerging that a variety of cytokines
are involved in cutaneous in£ammatory and immu-
nological reactions [1]. Release of cytokines by ker-
atinocytes can be induced by a number of environ-
mental factors, including trauma, ultraviolet light
and bacterial endotoxins. Macrophage migration in-
hibitory factor (MIF) was the ¢rst lymphokine re-
ported to prevent the migration of macrophages
out of capillary tubes [2]. Recently, it was reported
that MIF mRNA expression was up-regulated dur-
ing peripheral nerve regeneration, suggesting its in-
volvement in wound healing [3]. The process of
wound healing is complex, consisting of in£amma-
tion, granulation and remodeling of tissues. Several
growth factors/cytokines play an important role in
tissue repair and enhance the wound healing process
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[4]. In this context, MIF induced in cases of tissue
damage is considered to contribute to the in£amma-
tory and immunological responses.
In 1989, human MIF cDNA was cloned for the
¢rst time from activated T-cells [5]. Following this,
MIF genes of other species, including the mouse and
rat, were cloned [6,7]. After the cloning, extensive
molecular-based studies on MIF have been per-
formed. Recent ¢ndings demonstrated that MIF
functions as an initiator of in£ammation via regula-
tion of a number of pro-in£ammatory cytokines, in-
cluding tumor necrosis factor (TNF)-K, interleukin
(IL)-1 and IL-6 [8^10]. We demonstrated the expres-
sion and tissue localization of MIF in various tissues
such as epithelial and endothelial cells of the cornea,
reproductive organs, osteoblasts and kidney [11^14].
At present, MIF is known to function as a pituitary
hormone and glucocorticoid cytokine as well as an
immunomodulatory protein and is believed to be as-
sociated with broad-spectrum biological responses
beyond the immune system [15].
As for the skin, we demonstrated the presence and
tissue localization of MIF in the basal layers of hu-
man epidermis [16]. We identi¢ed a high expression
of MIF in atopic dermatitis and showed that MIF is
an immunoregulatory protein in the pathophysiology
of this skin disease [17]. We also showed that total-
body ultraviolet B exposure in vivo increased the
production of MIF, suggesting its involvement in
tissue injuries [18]. From these previous ¢ndings, it
is conceivable that MIF might be associated with
in£ammation and wound healing processes in vari-
ous skin disorders. In this study, we examined MIF
expression during the wound healing process of rat
skin. Following this, we assessed the e¡ect of MIF
on keratinocyte migration in vitro and evaluated the
e¡ects of anti-MIF antibodies on wound repair in
vivo.
2. Materials and methods
2.1. Materials
The following materials were obtained from com-
mercial sources. Isogen RNA extraction kit from
Nippon Gene (Tokyo, Japan); M-MLV reverse tran-
scriptase, trypsin-EDTA and fetal calf serum (FCS)
from Gibco (Grand Island, NY, USA); Taq DNA
polymerase from Perkin-Elmer (Norwalk, CO,
USA); horseradish peroxidase-conjugated goat anti-
rabbit antibody from Pierce (Rockford, IL, USA);
Vector ABC kit from Vector Laboratories (Burlin-
game, CA, USA); lipopolysaccharide (LPS) (0111:
B4) from Difco (Detroit, MI, USA); type I collage-
nase from Sigma (St. Louis, MO, USA); Protein A
Sepharose from Pharmacia (Uppsala, Sweden); Tis-
sue-Tek O.C.T compound from Miles Scienti¢c (Elk-
hart, MN, USA); polyvinyl alcohol sponges from
Mentor (Mingham, MA, USA); cellulose acetate
membrane ¢lter (8 Wm pores) from Kurabo (Osaka,
Japan); non-immune rabbit IgG and £uorescein iso-
thiocyanate-conjugated goat anti-rabbit IgG from
Zymed (San Francisco, CA, USA) and random
primer £uorescein labelling kit and nucleic acid
chemiluminescence reagent from DuPont NEN
(Boston, MA, USA). All other chemicals were of
analytical grade.
A polyclonal anti-rat MIF antibody was generated
by immunizing New Zealand white rabbits with pu-
ri¢ed recombinant rat MIF [19] and its speci¢city to
MIF protein was con¢rmed by Western blot analysis
as described [20]. The IgG fractions (4 mg/ml) were
prepared using Protein A Sepharose according to the
manufacturer’s protocol.
2.2. Preparation of rat skin tissues
All experiments were carried out on 7-week-old
Wistar King female rats weighing 150^170 g each.
The rats were anesthetized by a combination of ket-
amine and xylazine. After the abdominal surfaces
were shaved and wiped with 30% isopropyl alcohol,
six full-thickness wounds (6 mm diameter) on the
skin were made by excising the skin. The wounds
were allowed to be dry in order to form a scab.
Following killing with a pentobarbital overdose, the
skin specimens were harvested 1, 3, 6, 12, 24 or 48 h
after the injury. An area 1 mm in diameter, including
the complete epithelial margins, was excised at each
time point. Control rats were treated in a similar
manner without making wounds after the abdominal
surfaces were carefully shaven. Similar amounts of
the skin tissues from the abdominal walls of non-
wounded rats were obtained at the indicated inter-
vals as a control. The tissues were immediately fro-
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zen in liquid nitrogen and stored at 380‡C until used
for total RNA extraction.
2.3. Fibroblast culture
Wound ¢broblasts were obtained from the granu-
loma of injured skin lesions attached to polyvinyl
alcohol sponges (5U5U30 mm3 a piece) as described
[21]. In brief, the polyvinyl alcohol sponges were
placed under aseptic conditions into the £anks of
the rats. The sponges were allowed to stay for ap-
proximately 2 weeks, aseptically removed, minced
into ¢ne pieces and subjected to 4^6 h incubation
with collagenase (200 U/ml). At the end of collage-
nase digestion, the tissue specimens were subjected to
trypsin-EDTA treatment for 3 min. The cells were
then washed twice, plated in culture £asks and al-
lowed to grow to con£uence.
Normal dermal ¢broblasts were obtained from the
dorsal skin surface of the rat. The back of the rat
was carefully shaven, a segment of skin was excised
and ¢broblasts were obtained by the standard ex-
plant technique as described [22]. Brie£y, the skin
was cut into 3^5 mm pieces and placed onto large
petri dishes with the subcutaneous side down. Once a
su⁄cient number of ¢broblasts had migrated out
from the skin sections, pieces of the skin were re-
moved and the cells were passaged by trypsin diges-
tion in the same manner as for the wound-harvested
¢broblasts. Both the normal and the wound-har-
vested ¢broblasts were grown in DMEM containing
10% FCS and penicillin/streptomycin. The cells of
passages 2^4 were used for the experiment.
2.4. LPS stimulation
Cells were passaged twice prior to stimulation with
LPS. Immediately prior to stimulation, media con-
taining 10% FCS were removed and 1 Wg/ml of LPS
was added to serum-free DMEM. Supernatants were
collected 48 h after the stimulation and subjected to
an enzyme-linked immunosorbent assay (ELISA) for
MIF.
2.5. Reverse transcription-polymerase chain reaction
(RT-PCR) and Southern blot analysis
The skin specimens were surgically obtained from
the wound and normal rats as described above. Total
RNA was extracted from the specimens with an Iso-
gen RNA extraction kit. The reverse transcription of
RNA was carried out using M-MLV reverse tran-
scriptase with oligo-dT primers and subsequent am-
pli¢cation using Taq DNA polymerase. For analysis
of the MIF mRNA expression level, we preliminarily
examined the kinetics of MIF mRNA ampli¢cation
by semi-quantitative RT-PCR/Southern blot analy-
sis. The ampli¢cation of MIF mRNA remained in
the exponential phase up to at least 23 cycles. Since
the ampli¢cation products at 23 cycles could not be
visualized on an electrophoresed agarose gel stained
with ethidium bromide, we carried out Southern blot
hybridization to detect and quantify the ampli¢ed
products. As for glyceraldehyde-3-phosphate-dehy-
drogenase (G3PDH), linearity was similarly obtained
at 23 cycles and ampli¢cation was carried out in the
same way. In brief, the PCR was carried out for
23 cycles of denaturation at 94‡C for 1 min, anneal-
ing at 53‡C for 2 min and extension at 72‡C for
1 min using a thermal cycler (Perkin-Elmer, Model
2400). The primers for MIF were 5P-CACCA-
TGCCTATGTTCATCGTGAACA-3P (34^22, for-
ward) and 5P-AACGGTTCCACCTTCGCTTGAG-
CCCGGGC-3P (325^351, reverse) and those for
G3PDH were 5P-TGAAGGTCGGTGTCAACG-
GATTTGGC-3P (5^30, forward) and 5P-GTGG-
TGGACCTCATGGCCTACATG-3P (964^987, re-
verse). For numbering of the primers, the initial
nucleotide of the initiator methionine was designated
+1. The PCR products were separated on a 2% agar-
ose gel and transferred onto a nylon membrane by
capillary action. The DNA was immobilized on the
membrane by baking at 80‡C for 2 h. The DNA
probes for MIF and G3PDH were prepared using
the full-length rat MIF and G3PDH cDNA insert
labelled with a £uorescein labelling kit according to
the manufacturer’s protocol. Hybridization was car-
ried out in a solution containing 2Ustandard saline
citrate (SSC), 0.5% (w/v) dextran sulfate, 1 mg/ml
salmon sperm DNA, 0.1% sodium dodecyl sulfate
(SDS) and the £uorescein-labelled DNA probe at
65‡C, overnight. The membrane was washed in
2USSC containing 1% SDS at 65‡C for 15 min
and 0.2USSC containing 0.1% SDS at 65‡C for
15 min. The bands were visualized by a nucleic
acid chemiluminescence reagent. Quantitative analy-
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sis was carried out using a MCID image analyzer
(Fuji Film, Tokyo, Japan).
2.6. Immunohistochemistry
The samples from the rat skin at 12 h after injury
were immediately embedded in O.C.T. compound,
snap frozen in liquid nitrogen and stored at 380‡C
until further processing. The frozen embedded tissues
were cut into 4 Wm sections and then ¢xed in acetone
for 10 min at room temperature and subjected to
immunohistochemical analysis as described previ-
ously [12]. As a control, we used non-immune rabbit
IgG to exclude non-speci¢c staining.
2.7. ELISA
The injured and non-injured rats were killed by an
overdose of pentobarbital, blood of each rat was
obtained from the left ventricle and sera were pre-
pared. The sera as well as supernatants of cultured
¢broblasts were subjected to ELISA for measure-
ment of MIF as previously described [12]. For this
assay, we used recombinant rat MIF to obtain the
standard curve, in which good linearity was demon-
strated between MIF contents (0.5^200 ng/ml) and
absorbancy.
2.8. Chemotaxis assay
To evaluate the e¡ect of MIF on keratinocyte mi-
gration, a modi¢cation of the Boyden chamber assay
was performed as previously described [23]. Brie£y,
the lower well was ¢lled with 600 Wl of medium
(DMEM containing 10% FCS) in the presence of
various amounts of MIF. The upper well contained
the cell suspension (400 Wl, 1U105 cells/ml medium).
A cellulose acetate membrane ¢lter was interposed
between the two chambers. The chambers were
kept in a humidi¢ed atmosphere of 5% CO2 at
37‡C for 4 h. Filters were subsequently ¢xed with
methanol and acetone and stained with crystal violet.
The number of cells that migrated into the ¢lter and
reached its lower side was determined microscopi-
cally. Three chambers were set up for each assay,
¢ve ¢elds were counted on each ¢lter and the counts
were expressed as means with S.D. In each experi-
mental group, a negative control (medium) was run.
2.9. Wound healing experiments
For wound healing experiments, mice (C57/BL6,
female 6^8 weeks), weighing 25^30 g, were anesthe-
tized with sodium pentobarbital solution (40 mg/kg,
intraperitoneal (i.p.)) and their dorsal hair was
clipped. Four penetrating wounds through both the
epidermis and dermis were prepared on the upper
back of each mouse using a punch biopsy instrument
(4 mm diameter). The four wounds were separated
by 1 cm. The wounds were left open during the ex-
periments. Anti-rat MIF antibodies (5 mg/kg) which
cross react with mouse MIF [6,7] or non-immune
rabbit IgG were injected i.p. (5 mg/kg) every 2 days
(starting on day 0) until wound healing was com-
pleted. We examined the appearance of the skin
wound lesions until the epithelial surface was re-
stored.
2.10. Statistics
Statistical analyses on the MIF levels in the culture
media of the normal and wounded ¢broblasts and of
the keratinocyte migration by the Boyden chamber
assay were performed using Student’s t-test and the
Mann-Whitney U-test, respectively. P6 0.05 was
considered to be signi¢cant.
3. Results
3.1. Induction of MIF mRNA during wound healing
We examined the expression of MIF mRNA in the
wound healing of rat skin by RT-PCR/Southern blot
analysis until 48 h after injury. The results showed a
biphasic increase of MIF mRNA (Fig. 1). In detail,
the MIF mRNA expression level was signi¢cantly
elevated at 1 h after the injury and reached the max-
imal level at 3 h (ca. 1.8-fold) and rapidly decreased
at 6 h. Then, the MIF expression was again increased
at 24 h (ca. 2.6-fold) after the injury and decreased at
48 h. As an internal control, the mRNA of G3PDH
was measured.
3.2. MIF content in sera during wound healing
The serum MIF protein concentration of the in-
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jured rats was measured at regular intervals. The
results showed a similar biphasic increase in the ex-
pression of MIF mRNA (Fig. 2). The serum content
before the injury was 8.1 þ 1.8 ng/ml. The ¢rst peak
was observed at 3 h (56.8 þ 9.9 ng/ml) after the skin
injury with a signi¢cant di¡erence, but rapidly de-
creased at 6 h after injury. The second peak of
MIF protein was identi¢ed at 24 h (56.7 þ 15.0 ng/
ml) after the injury and gradually decreased at 48 h.
Since £uorescence-labelled MIF was taken up by
melanoma cells and macrophages in vitro (unpub-
lished observation), it was speculated that the tran-
sient decrease of MIF between 6^24 h, even if not
completely, might be attributable to the uptake by
cells of various organs in vivo.
3.3. Immunohistochemical localization of MIF in
wounded rat skin
Immunohistochemical analysis was carried out on
the tissues obtained at 12 h after injury. It was re-
vealed that MIF-positive staining was mostly ob-
served in the basal layer of the control (Fig. 3A) as
previously demonstrated [16]. On the other hand,
extensive positive staining was observed in all the
layers of the epidermis that reacted with the anti-
MIF antibody after the injury (Fig. 3B). In addition,
some positive mononuclear cells were also observed
in the dermis. The positive staining was not detected
when non-immune IgG was used (Fig. 3C).
3.4. MIF expression of cultured wound ¢broblasts
Fibroblasts play an important role in the wound
healing process of the skin, equal to that of kerati-
nocytes. For examining the process of wound heal-
ing, LPS has sometimes been used as a stimulant and
the mechanism of in£ammatory and immune re-
sponses in the event of tissue damage has been eval-
uated [21,24]. To determine whether the wound ¢-
broblasts and the normal dermal ¢broblasts could
secrete MIF in response to LPS, we measured the
MIF content in the media of both the wound and
normal dermal ¢broblasts in response to LPS stim-
ulation under serum-free conditions. Fig. 4 shows
that MIF secretion by the wound ¢broblasts was
signi¢cantly higher than that of normal dermal ¢bro-
blasts with and without stimulation. The wound ¢-
Fig. 2. Serum MIF levels after skin injury. Serum samples from
the rats were obtained before and at 1, 3, 6, 12, 24 and 48 h
after injury. MIF was evaluated by a MIF-speci¢c ELISA as
described in Section 2. Results are expressed as mean þ S.D. of
¢ve di¡erent experiments.
Fig. 1. MIF mRNA expression in rat skin. Total RNA was iso-
lated from rat skin before and after injury by excision. RT-
PCR/Southern blot analysis was performed as described in Sec-
tion 2. (A) A typical expression pattern of MIF mRNA of
three independent experiments is shown and that of G3PDH is
also presented as an internal control. (B) The relative MIF
mRNA expression normalized by G3PDH mRNA is shown.
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broblasts treated with LPS for 48 h signi¢cantly in-
creased secretion of the MIF protein into the culture
medium (2.9 þ 0.2 ng/ml) compared to normal der-
mal ¢broblasts (0.8 þ 0.1 ng/ml).
3.5. Chemotactic e¡ect of MIF on keratinocyte
migration
Migration of keratinocytes is an important event
for wound healing of the skin. To assess the role of
MIF in wounds, freshly separated rat keratinocytes
obtained from wound lesions were tested for chemo-
tactic activity of this protein. We added various
doses of MIF in the lower chamber at concentrations
of 1, 10 and 100 ng/ml. A signi¢cant increase of
keratinocyte migration was observed at the highest
dose of MIF (100 ng/ml) (Fig. 5). Since the MIF
concentration is increased at the level of 80^120 ng/
ml at loci such as synovial £uids and follicular £uids
[25,26], it is conceivable that the local MIF concen-
tration at the site of skin wounds might reach these
levels to induce keratinocyte migration in vivo.
Fig. 4. Stimulation of wound ¢broblasts and normal dermal ¢-
broblasts with LPS. The MIF content was measured in the cul-
ture media of wound and normal dermal ¢broblasts stimulated
with a 1 Wg/ml dose of LPS under serum-free conditions using
an ELISA for MIF. Results are expressed as mean þ S.D. of
three di¡erent experiments. *, P6 0.005; **, P6 0.0005.
Fig. 3. Immunohistochemical analysis of MIF expression in the
skin wound lesion. Skin biopsy was carried out on normal ab-
dominal skin and at 12 h after injury. Tissue specimens for im-
munohistochemical analysis obtained from the normal skin (A)
(U100) and the wound lesion (B) were stained with a Vector
ABC immunostaining kit using an anti-rat MIF antibody
(U100). Arrowheads in A indicate the basal cell layers and ar-
rowheads and arrows in B demonstrate a wound edge and
mononuclear cells, respectively. No speci¢c positive staining
was observed by using non-immune rabbit IgG (C) (U100), in
which arrowheads indicate a wound edge. E and D denote epi-
dermis and dermis, respectively. Bars, 50 Wm.
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3.6. E¡ect of anti-MIF antibody on wound healing of
the skin
We observed that the reparative pattern was char-
acterized by formation of a dehydrated wound crust,
gradual loss of the lesion surface, appearance of a
thin residual skin defect, closure of the wound
surface and re-appearance of the epithelial surface.
We examined the appearance of round skin wounds
after treatment with anti-MIF antibodies to assess
the role of MIF in the wound healing process.
Complete healing was seen between 5 and 9 days
after the surgery for the control mice injected with
non-immune IgG, whereas it was seen between
11 and 15 days for the mice injected with anti-MIF
antibodies (Fig. 6). This fact indicated that MIF
played an important role in the wound healing proc-
ess.
4. Discussion
We demonstrated increased MIF expression in the
wound healing process and MIF production by
wound ¢broblasts was increased by LPS. MIF acted
as a chemoattractant for keratinocytes. Moreover, it
should be noted that the wound healing process was
signi¢cantly delayed by administration of anti-MIF
antibody in vivo. These ¢ndings strongly indicated
that pluripotent MIF could play a critical role in
skin injury, a¡ecting cutaneous immunity, in£amma-
tion and cell growth.
Numerous investigations have demonstrated that
several cytokines play pivotal roles in the patho-
physiology of the normal skin and related diseases
[1]. For example, IL-1K, which is produced by kera-
tinocytes and other cells, stimulates the growth of
¢broblasts and keratinocytes, collagen synthesis by
¢broblasts and chemotaxis of keratinocytes in tissue
injuries [27]. The wound healing process of the skin is
complex, consisting of clotting, in£ammation, ¢bro-
plasia, neovascularization, wound contraction and
tissue remodeling, in which collaborative actions of
many di¡erent tissues and cell lineages are required
[28]. Histologically, migration of keratinocytes from
the wound edges and their subsequent proliferation
are essential for wound repair [29]. In this process,
cytokines and other in£ammatory mediators released
from keratinocytes govern this event by regulating
the growth, di¡erentiation and metabolism of the
various cells in the injured skin lesion [4].
After discovery of MIF activity in the culture
supernatant of activated T-cells [30], various biolog-
ical activities of MIF were reported. However, the
MIF gene was long unidenti¢ed. In 1989, human
Fig. 6. E¡ects of anti-MIF antibodies on healing of skin wound
lesions. Wound healing appearance was assessed after treatment
with anti-MIF antibodies in mice. The number of mice with
complete healing of four skin lesions was plotted at di¡erent
time points after penetrating wounds through both the epider-
mis and dermis. (E), anti-MIF antibodies (n = 7); (b), non-im-
mune IgG (n = 7). *, P6 0.0045.
Fig. 5. Chemotaxis of freshly separated rat keratinocytes in re-
sponse to di¡erent doses of MIF. The culturing method and
chemotaxis assay are described in Section 2. *, P6 0.005.
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MIF cDNA was cloned for the ¢rst time from acti-
vated T-cells, although this molecule was found to be
distinct from the previously known MIF molecules
and found to be a novel protein with respect to ami-
no acid sequences. Following this, MIF genes of var-
ious species were isolated, including mouse, rat and
chicken [6,7,31].
After the molecular cloning of MIF, this protein
was rediscovered as an immunomodulatory cytokine
induced by a number of stimuli such as LPS, modu-
lates in£ammatory and immunological responses and
functions as an initiator of in£ammatory and immu-
nological reactions by regulating production of a
number of cytokines, including TNF-K, IL-1 and
IL-6 [8,9]. In this study, we demonstrated for the ¢rst
time up-regulation of MIF in the wound healing
keratinocytes by immunohistochemical and RT-
PCR/Southern blot analyses. In parallel, we showed
that the serum MIF level was increased. The source
of elevated serum MIF was not clearly identi¢ed, but
it is very likely that keratinocytes and ¢broblasts in
the wound skin are the major sources. Moreover, we
found elevation of MIF production by cultured
wound ¢broblasts. It is known that ¢broblasts con-
tribute to wound healing. Endotoxin administration
a¡ects the expression of MIF protein and mRNA in
various tissues of the rat [10], but no precise exami-
nation of MIF functions has been performed in the
skin. This is the ¢rst evidence demonstrating up-reg-
ulation of MIF in cultured ¢broblasts in response to
LPS. In association with the source of serum MIF, it
was reported that MIF was readily secreted from the
pituitary in response to various stimuli such as endo-
toxins as a counter-regulator of glucocorticoid [32].
Accordingly, the elevation of the serum MIF content
may also have originated from the pituitary.
Investigations focused on the role of ¢broblast-se-
creted cytokines in in£ammatory responses have re-
cently been carried out, because ¢broblasts have been
regarded as candidate cells for the production of
various cytokines and growth factors found in the
wound milieu. Indeed, cultured ¢broblasts obtained
from wound lesions are capable of secreting TNF-K
after LPS stimulation [21]. To date, several reports
support the idea that ¢broblasts have the potential to
secrete a broad range of cytokines and growth fac-
tors, including IL-1, IL-6 and colony-stimulating fac-
tors [33]. Since TNF-K up-regulates MIF production
of macrophages and various other types of cells [34^
36] and vice versa [9], the presence of an amplifying
pro-in£ammatory loop response between the two cy-
tokines is hypothesized.
Cell proliferation and di¡erentiation are essential
for wound healing. The possible involvement of MIF
in cell di¡erentiation and proliferation has been re-
ported. For example, MIF is present in highly pro-
liferative tissues such as the corneal epithelium [12],
basal cell layers of skin epidermis [16], osteoblasts
[13], leukemia cells [37] and the early embryonal
chicken lens [31]. MIF may a¡ect cellular prolifera-
tion as a growth factor-induced delayed early re-
sponse gene [38]. We recently found that the MIF
mRNA of the injured cornea was up-regulated at
6 h after injury [20]. This ¢nding supported the
idea that MIF is associated with the acute phase of
the wound healing process and is consistent with our
present results on the skin injury. Therefore, up-reg-
ulation of MIF after the injury as a delayed early
response gene appears to be reasonable. Further-
more, we observed that antisense MIF plasmid trans-
fection suppressed the growth of tumor cells and the
morphological changes of these cells (unpublished
data). Although the precise mechanism of the molec-
ular function of MIF in relation to cell growth re-
mains to be elucidated, these ¢ndings support the
idea that excessive expression of MIF may directly
or indirectly stimulate cell proliferation, which mod-
ulates the wound healing process.
Finally, the reparative response to a skin wound is
accompanied by migration of keratinocytes, which
contributes to wound repair. We here demonstrated
that MIF had the potential to induce keratinocyte
migration in vitro and, moreover, anti-MIF antibody
caused a delay in the closure of the skin wound. In
this context, it is considered that MIF may play an
important role in the skin wound healing process.
The pathophysiological function of MIF should
thus be a major target of research in association
with wound healing of the skin.
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